Five thousand pediatric-only rare conditions, or “orphan diseases,” lack a market large enough to drive intervention. American universities can change that by serving as a development force to conduct research in therapeutics and biomedical technologies for children.
Subscribe to:
Post Comments (Atom)
< + > Beyond Data Exchange: The Next Era of Interoperability Happens Inside Clinical Workflows
The following is a guest article by Jonathan Shoemaker , CEO at ABOUT Healthcare For a time period that seems like just about forever, the ...
No comments:
Post a Comment